Application of pingyangmycin combined with sodium hyaluronate in drug for treating lymphatic malformation

Abstract

The invention discloses an application of pingyangmycin combined with sodium hyaluronate in a drug for treating lymphatic malformation, as well as a drug for treating lymphatic malformation, in particular to a drug for treating microcystic lymphatic malformation. According to the application, the pingyangmycin combined with the sodium hyaluronate is adopted and has better effects in the aspects of inhibiting human lymphatic malformation endothelial cell proliferation and promoting apoptosis while compared with pure pingyangmycin, wherein the molecular weight of the sodium hyaluronate is 600,000 Dalton-1,500,000 Dalton, and concentrations of the pingyangmycin and the sodium hyaluronate are 100 mu g / mL and 300 mu g / mL respectively.

Description

technical field [0001] The invention relates to the application of pingyangmycin combined with sodium hyaluronate in the treatment of lymphatic malformation. Background technique [0002] Lymphatic malformations are congenital vascular malformations. According to the clinical and histobiological characteristics of vascular diseases, lymphangiomas are classified as lymphatic malformations, which are divided into macrocystic and microcystic. About 50% of patients with lymphatic malformations were discovered at birth, and 80% to 90% of the lesions occurred within two years of age, and most often occurred in the tongue, neck, cheeks, and lips. Its pathogenesis is unknown, and some experts believe that lymphatic malformation may be related to gene mutations encoding VEGF-C, VEGFR-3, FOX-C2 and SOX-18. Although lymphatic malformation is a benign lesion, its natural regression rate is about 2%-12.5%. Some patients may rapidly increase due to trauma and infection of the diseased ti...

AI Technical Summary

Problems solved by technology

①Pleomycin has less side effects, but it will increase the risk of pulmonary fibrosis when combined with renal insufficiency

②Because the microcystic lymphatic malformation has multiple cystic cavities, it is difficult to extract all the liquid in the cavity, and the drug cannot fully contact with all the cystic walls in the tumor body, resulting in poor effect

③Due to the limitation of the drug dose, it is not possible to administer drugs to all lesion areas with large lymphatic malformations in the maxillofacial region of infants and young children at the same time, and there is a contradiction between the lesion range and the drug dose

④ For lesions with a large head and neck area, the lymphatic circulation is rich and the reflux is fast. Pingyangmycin is diluted soon after injection, the action time is short, and it is difficult to directly contact the cyst wall to exert its effect, so the clinical effect is not ideal , if the dose or concentration of the drug is increased, the corresponding side effects will also increase

Images